Research on abortion
Search publications
Research on Abortion
Research at ANSIRH
Research on Contraception
Research on Culture
International Research
Research on Policy
ANSIRH publications
ANSIRH publications
ANSIRH publications & resources
ANSIRH publications
ANSIRH training materials
ANSIRH training materials
ANSIRH in the Media
ANSIRH publications & resources
ANSIRH resources
ANSIRH resources
ANSIRH resources

Research project

Over-the-Counter Medication Abortion

- back to Novel Abortion Provision Models

Current regulations restrict access to medication abortion and contribute to the perception that people cannot safely take medication abortion pills (mifepristone and misoprostol) on their own without clinician supervision. Yet, mifepristone and misoprostol meet many of the FDA’s criteria for being available over the counter. They are safe, have no risk of overdose, are not addictive, and people are already using them safely on their own in many parts of the world. The possibility of an over-the-counter medication abortion model would involve the medications being available without a prescription in a drug store or grocery, similar to emergency contraception or condoms and pregnancy tests. The pills would come with detailed instructions as well as information about access to a number of different resources, such as a 24-hour telephone number to call with questions about the medication.

There are several areas, such as whether people can accurately assess their gestational age, that require further research. ANSIRH researchers are conducting a series of preliminary studies to address these gaps and to demonstrate whether medication abortion is appropriate for over-the-counter use. In this study, we will investigate whether individuals can:

  • Understand a Drug Facts Label,
  • Assess gestational age and rule out other contraindications for medication abortion,
  • Self-administer the medications according to instructions, and
  • Identify complications and know when to seek medical care, including for ongoing pregnancy.   

In the short term, these efforts will help support a wide variety of efforts aimed at improving access to clinic-based and self-managed medication abortion. In the long term, FDA approval of an OTC mifepristone-misoprostol product could dramatically increase access to medication abortion.

Sign up for the ANSIRH Listserv

Want to stay up to date on the latest research and news from ANSIRH? Join our listserv.

Contact us

Connect with us on social media

ANSIRH is a program within the UCSF Bixby Center for Global Reproductive Health and is a part of UCSF's Department of Obstetrics, Gynecology & Reproductive Sciences.

©2015 The Regents of the University of California